Ann-Lii Cheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6775333/publications.pdf

Version: 2024-02-01

545 papers	45,794 citations	7069 78 h-index	2558 195 g-index
559 all docs	559 docs citations	559 times ranked	33042 citing authors

#	Article	IF	Citations
1	Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1803-1811.	1.2	2
2	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. British Journal of Cancer, 2022, 126, 569-575.	2.9	10
3	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 38-47.	4.2	20
4	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	5.1	526
5	IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.. Journal of Clinical Oncology, 2022, 40, 470-470.	0.8	6
6	Cyclin dependent kinase 9 inhibition as a potential treatment for hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 425-425.	0.8	1
7	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 862-873.	1.8	568
8	Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers, 2022, 14, 1005.	1.7	11
9	Abstract P2-01-09: Clinical impact of ESR1 mutation ctDNA on survival outcome is dependent on PI3KCA/TP53 ctDNA mutation status. Cancer Research, 2022, 82, P2-01-09-P2-01-09.	0.4	0
10	Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer, 2022, 126, 1806-1814.	2.9	11
11	Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Childâ€"Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer, 2022, 22, 377.	1.1	10
12	Immune checkpoint inhibitors for hepatocellular carcinoma â€" A game changer in treatment landscape. Journal of the Formosan Medical Association, 2022, 121, 1371-1383.	0.8	3
13	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.	1.3	43
14	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical Cancer Research, 2022, 28, 2547-2554.	3.2	32
15	Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. European Journal of Cancer, 2022, 168, 91-98.	1.3	3
16	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
17	Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208.. Journal of Clinical Oncology, 2022, 40, e16181-e16181.	0.8	0
18	Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 995-1008.	5.1	237

#	Article	IF	Citations
19	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. Journal of the Formosan Medical Association, 2021, 120, 293-302.	0.8	4
20	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.. Journal of Clinical Oncology, 2021, 39, 297-297.	0.8	4
21	Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. OncoImmunology, 2021, 10, 1973710.	2.1	4
22	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2021, 39, 267-267.	0.8	226
23	Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 268-268.	0.8	10
24	ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399.	1.4	7
25	Pursuing efficacious systemic therapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 95-96.	8.2	9
26	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 318-318.	0.8	0
27	Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2021, 144, 291-301.	1.3	8
28	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2021, 26, 422-426.	1.9	8
29	Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. , 2021, 9, e001657.		63
30	Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort. British Journal of Cancer, 2021, 125, 48-54.	2.9	1
31	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer, 2021, 10, 275-284.	4.2	29
32	Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, e16122-e16122.	0.8	0
33	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 200-208.	2.9	22
34	Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology, 2021, 56, 570-580.	2.3	6
35	Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology, 2021, 39, 4074-4074.	0.8	1
36	IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).. Journal of Clinical Oncology, 2021, 39, 4071-4071.	0.8	21

#	Article	IF	Citations
37	Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology, 2021, 39, 4072-4072.	0.8	2
38	IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.. Journal of Clinical Oncology, 2021, 39, 4073-4073.	0.8	52
39	Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 346-359.	4.2	70
40	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1340.	1.3	6
41	Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells, 2021, 10, 1698.	1.8	5
42	Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung Journal of Medical Sciences, 2021, 37, 643-653.	0.8	11
43	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. Npj Breast Cancer, 2021, 7, 88.	2.3	8
44	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	1.8	17
45	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 991-1001.	5.1	179
46	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-ÎºB-related signaling. Cancer Cell International, 2021, 21, 436.	1.8	4
47	P024â€…KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. , 2021, , .		1
48	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
49	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	0.8	257
50	Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients. Breast, 2021, 59, 211-220.	0.9	2
51	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers, 2021, 13, 5142.	1.7	2
52	Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers, 2021, 13, 4962.	1.7	3
53	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. Journal of the Formosan Medical Association, 2020, 119, 335-344.	0.8	8
54	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Journal of the Formosan Medical Association, 2020, 119, 97-105.	0.8	3

#	Article	IF	Citations
55	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Investigational New Drugs, 2020, 38, 99-110.	1.2	41
56	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 489-497.	1.8	38
57	Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 93-104.	4.2	60
58	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	0.8	1,255
59	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2020, 73, 1460-1469.	1.8	254
60	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	2.0	51
61	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Haematologica, 2020, 105, e349-e354.	1.7	5
62	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Advances in Therapy, 2020, 37, 2678-2695.	1.3	37
63	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 382, 1894-1905.	13.9	3,828
64	Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology, 2020, 16, 1525-1536.	1.1	50
65	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1324-1332.	2.9	23
66	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4795-4804.	3.2	58
67	A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. Environment International, 2020, 142, 105850.	4.8	48
68	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	1.8	310
69	Milestones in the pathogenesis and management of primary liver cancer. Journal of Hepatology, 2020, 72, 209-214.	1.8	39
70	Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. Oncologist, 2020, 25, e16-e23.	1.9	40
71	Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival. Journal of Neuro-Oncology, 2020, 148, 165-172.	1.4	17
72	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology, 2020, 16, 975-989.	1.1	136

#	Article	IF	Citations
73	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. Oncologist, 2020, 25, e1280-e1285.	1.9	14
74	Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology, 2020, 38, 4508-4508.	0.8	86
75	Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.. Journal of Clinical Oncology, 2020, 38, 4587-4587.	0.8	2
76	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 4596-4596.	0.8	7
77	Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 476-476.	0.8	28
78	Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 518-518.	0.8	15
79	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. Journal of Clinical Oncology, 2020, 38, 526-526.	0.8	5
80	RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).. Journal of Clinical Oncology, 2020, 38, 528-528.	0.8	1
81	Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial.. Journal of Clinical Oncology, 2020, 38, 1082-1082.	0.8	0
82	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 76-82.	0.9	10
83	Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2020, 38, 520-520.	0.8	2
84	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer, 2019, 8, 110-120.	4.2	46
85	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 155-171.	4.2	25
86	Early alphaâ€fœtoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver International, 2019, 39, 2184-2189.	1.9	55
87	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 480-490.	4.2	57
88	Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer. Cancers, 2019, 11, 1204.	1.7	11
89	Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 2019, 121, 218-221.	2.9	22
90	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers, 2019, 11, 1433.	1.7	13

#	Article	IF	Citations
91	Klothoâ€beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Liver International, 2019, 39, 1682-1691.	1.9	19
92	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	1.4	5
93	FRI-471-Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization. Journal of Hepatology, 2019, 70, e605-e606.	1.8	18
94	Phase II APEC trial: The impact of primary tumor side on outcomes of firstâ€line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wildâ€type metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 225-230.	0.7	5
95	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. Journal of the National Cancer Institute, 2019, 111, 1298-1306.	3.0	83
96	Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Cancers, 2019, 11, 547.	1.7	30
97	Phase I Study of the Focal Adhesion Kinase Inhibitor BIÂ853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Targeted Oncology, 2019, 14, 57-65.	1.7	20
98	CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer. Oncology, 2019, 96, 156-163.	0.9	6
99	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association, 2019, 118, 1024-1030.	0.8	5
100	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 4004-4004.	0.8	149
101	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.. Journal of Clinical Oncology, 2019, 37, TPS4152-TPS4152.	0.8	94
102	Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.. Journal of Clinical Oncology, 2019, 37, TPS4157-TPS4157.	0.8	24
103	Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).. Journal of Clinical Oncology, 2019, 37, 186-186.	0.8	35
104	Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.. Journal of Clinical Oncology, 2019, 37, 207-207.	0.8	19
105	Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 305-305.	0.8	2
106	Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.. Journal of Clinical Oncology, 2019, 37, 316-316.	0.8	1
107	Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).. Journal of Clinical Oncology, 2019, 37, 317-317.	0.8	26
108	Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 371-371.	0.8	10

#	Article	IF	Citations
109	Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 423-423.	0.8	7
110	Hypofractionated particle beam therapy for hepatocellular carcinomaâ€"a brief review of clinical effectiveness. World Journal of Gastrointestinal Oncology, 2019, 11, 579-588.	0.8	5
111	Expression of human leukocyte antigen-a and b2-microglobulin in prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16550-e16550.	0.8	1
112	Targeting tumorâ€infiltrating Ly6G⁺ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. International Journal of Cancer, 2018, 142, 1878-1889.	2.3	46
113	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology, 2018, 48, 242-247.	0.6	4
114	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2018, 7, 165-178.	4.2	23
115	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, The, 2018, 391, 1163-1173.	6.3	3,542
116	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. Journal of Hepatology, 2018, 69, 286-292.	1.8	76
117	Targeting histone deacetylase 4/ubiquitinâ€conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. Hepatology, 2018, 67, 586-599.	3.6	29
118	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Journal of the Formosan Medical Association, 2018, 117, 381-403.	0.8	92
119	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. The Lancet Gastroenterology and Hepatology, 2018, 3, 37-46.	3.7	127
120	Recent developments of câ€Met as a therapeutic target in hepatocellular carcinoma. Hepatology, 2018, 67, 1132-1149.	3.6	190
121	Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. Cancer Prevention Research, 2018, 11, 227-236.	0.7	31
122	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Seminars in Liver Disease, 2018, 38, 379-388.	1.8	62
123	Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer. European Radiology, 2018, 28, 4860-4870.	2.3	9
124	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	5.1	1,816
125	Effect of glucocorticoid use on survival in patients with stage Iâ€"III breast cancer. Breast Cancer Research and Treatment, 2018, 171, 225-234.	1.1	8
126	Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-ÎºB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells. PLoS ONE, 2018, 13, e0199779.	1.1	2

#	Article	IF	Citations
127	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	13.9	1,677
128	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research, 2018, 38, 4805-4812.	0.5	3
129	The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. Theranostics, 2018, 8, 3176-3188.	4.6	39
130	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 3534-3534.	0.8	1
131	Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.. Journal of Clinical Oncology, 2018, 36, 4018-4018.	0.8	65
132	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.. Journal of Clinical Oncology, 2018, 36, 4019-4019.	0.8	10
133	Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. Journal of Clinical Oncology, 2018, 36, 4020-4020.	0.8	9
134	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 4088-4088.	0.8	6
135	Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 4090-4090.	0.8	24
136	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4141-TPS4141.	0.8	38
137	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.. Journal of Clinical Oncology, 2018, 36, 207-207.	0.8	62
138	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. Journal of Clinical Oncology, 2018, 36, 209-209.	0.8	30
139	Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2018, 36, 345-345.	0.8	1
140	Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMISâ€"An international observational study assessing the use of sorafenib after TACE.. Journal of Clinical Oncology, 2018, 36, 368-368.	0.8	11
141	Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. Journal of Clinical Oncology, 2018, 36, 747-747.	0.8	1
142	The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	9
143	<scp>mRECIST</scp> to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase <scp>II</scp> trials comparing nintedanib vs sorafenib. Liver International, 2017, 37, 1047-1055.	1.9	58
144	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemotherapy and Pharmacology, 2017, 79, 421-429.	1.1	19

#	Article	IF	Citations
145	National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients. Oncologist, 2017, 22, 843-849.	1.9	19
146	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 56-66.	6.3	2,771
147	Asiaâ€"Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International, 2017, 11, 317-370.	1.9	1,537
148	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. Journal of the Formosan Medical Association, 2017, 116, 689-696.	0.8	9
149	Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood, 2017, 129, 188-198.	0.6	20
150	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology, 2017, 27, 3069-3079.	2.3	18
151	First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Scientific Reports, 2017, 7, 14333.	1.6	21
152	Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. Scientific Reports, 2017, 7, 9842.	1.6	25
153	Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open, 2017, 2, e000151.	2.0	9
154	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. Journal of Hepatology, 2017, 67, 999-1008.	1.8	465
155	The B-cell-activating factor signalling pathway is associated withHelicobacter pyloriindependence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21). Journal of Pathology, 2017, 241, 420-433.	2.1	13
156	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer. Supportive Care in Cancer, 2017, 25, 533-539.	1.0	12
157	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 2017, 16, e73-e88.	1.0	19
158	Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. Journal of Radiation Research, 2017, 58, 114-122.	0.8	12
159	High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Japanese Journal of Clinical Oncology, 2017, 47, 949-953.	0.6	37
160	Tumor compactness improves the preoperative volumetry-based prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy. Oncotarget, 2017, 8, 7921-7934.	0.8	15
161	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology, 2017, 35, 4001-4001.	0.8	65
162	Phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC): Final data including long-term outcomes.. Journal of Clinical Oncology, 2017, 35, 4087-4087.	0.8	3

#	Article	IF	Citations
163	Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict efficacy of axitinib for treatment of advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, e15656-e15656.	0.8	1
164	Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.. Journal of Clinical Oncology, 2017, 35, TPS4143-TPS4143.	0.8	3
165	Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2017, 35, 233-233.	0.8	9
166	KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS503-TPS503.	0.8	29
167	KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS504-TPS504.	0.8	8
168	Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer. PLoS ONE, 2017, 12, e0170942.	1.1	33
169	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE, 2017, 12, e0180628.	1.1	4
170	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. Oncotarget, 2017, 8, 81329-81342.	0.8	6
171	Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. Oncotarget, 2017, 8, 86681-86692.	0.8	11
172	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. Anticancer Research, 2017, 37, 2593-2599.	0.5	17
173	Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study. Anticancer Research, 2017, 37, 7095-7104.	0.5	6
174	Clinical and Preclinical Perspectives on Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 93-103.	0.1	2
175	Comparison of irinotecan and oxaliplatin as adjuvant chemotherapy for patients with resectable synchronous colon cancer plus liver-confined metastases: A retrospective nationwide database study.. Journal of Clinical Oncology, 2017, 35, 624-624.	0.8	0
176	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. Journal of Clinical Oncology, 2017, 35, 4042-4042.	0.8	14
177	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. Journal of Cancer, 2016, 7, 1515-1523.	1.2	9
178	Relapse Pattern and Treatment Outcome of Curative Radiotherapy for Primary Cutaneous CD30+ Anaplastic Large-cell Lymphoma: A Retrospective Cohort Study. Acta Dermato-Venereologica, 2016, 96, 394-395.	0.6	4
179	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 2004-2012.	1.4	5
180	BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. Medical Oncology, 2016, 33, 39.	1.2	22

#	Article	IF	Citations
181	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer, 2016, 16, 327.	1.1	42
182	A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. Journal of Biomedical Science, 2016, 23, 64.	2.6	21
183	Inhibition of the Wnt/Î²-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Letters, 2016, 381, 58-66.	3.2	39
184	Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1â€“2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy. Annals of Surgical Oncology, 2016, 23, 3860-3869.	0.7	29
185	Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer, 2016, 5, 128-138.	4.2	108
186	Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. Scientific Reports, 2016, 6, 21374.	1.6	17
187	A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer, 2016, 16, 466.	1.1	23
188	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1336-1341.	1.4	25
189	Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. Radiology, 2016, 281, 454-464.	3.6	33
190	Randomized, openâ€label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology, 2016, 64, 774-784.	3.6	77
191	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clinical Cancer Research, 2016, 22, 2555-2564.	3.2	42
192	Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis. Journal of the Formosan Medical Association, 2016, 115, 243-248.	0.8	17
193	Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells. Rna, 2016, 22, 303-315.	1.6	32
194	Effect of national policy changes on hospice utilization and the invasiveness of end-of-life care in cancer patients.. Journal of Clinical Oncology, 2016, 34, 10008-10008.	0.8	1
195	Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 4072-4072.	0.8	2
196	Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, TPS3103-TPS3103.	0.8	5
197	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7275.	1.4	26
198	Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.. Journal of Clinical Oncology, 2016, 34, e15695-e15695.	0.8	0

#	Article	IF	Citations
199	mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomized phase II trials comparing nintedanib versus sorafenib.. Journal of Clinical Oncology, 2016, 34, 4086-4086.	0.8	8
200	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma.. Journal of Clinical Oncology, 2016, 34, e19024-e19024.	0.8	0
201	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. Scientific Reports, 2015, 5, 17879.	1.6	11
202	Helicobacter pylori CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. American Journal of Surgical Pathology, 2015, 39, 761-766.	2.1	19
203	The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. World Journal of Surgical Oncology, 2015, 13, 312.	0.8	4
204	<scp>S</scp>onic <scp>H</scp>edgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1317-1324.	1.4	28
205	High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. PLoS ONE, 2015, 10, e0124908.	1.1	9
206	A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer, 2015, 15, 299.	1.1	56
207	High Serum Transforming Growth Factor-Î²1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. Clinical Cancer Research, 2015, 21, 3678-3684.	3.2	76
208	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1481-1489.	0.5	15
209	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer, 2015, 4, 96-105.	4.2	19
210	Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. Clinical Lung Cancer, 2015, 16, 137-143.	1.1	14
211	Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Letters, 2015, 357, 582-590.	3.2	44
212	Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials. Oncology, 2015, 88, 345-352.	0.9	31
213	Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. Journal of Hepatology, 2015, 63, 896-904.	1.8	44
214	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. Clinical Colorectal Cancer, 2015, 14, 177-184.e4.	1.0	36
215	Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clinical Cancer Research, 2015, 21, 1851-1858.	3.2	72
216	Primary central nervous system diffuse large Bâ€cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology, 2015, 67, 625-635.	1.6	25

#	Article	IF	Citations
217	Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 810-820.	1.9	26
218	Young patients with colorectal cancer have increased risk of second primary cancers. Japanese Journal of Clinical Oncology, 2015, 45, 1029-1035.	0.6	11
219	The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist, 2015, 20, 1051-1057.	1.9	13
220	AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-ÎºB activation. Leukemia and Lymphoma, 2015, 56, 2674-2682.	0.6	7
221	The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 19-31.	1.4	37
222	Heterogeneous cell origin of Helicobater pylori-dependent high-grade gastric lymphomas.. Journal of Clinical Oncology, 2015, 33, e19520-e19520.	0.8	1
223	Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 237-237.	0.8	5
224	Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. Journal of Clinical Oncology, 2015, 33, 339-339.	0.8	7
225	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).. Journal of Clinical Oncology, 2015, 33, TPS496-TPS496.	0.8	5
226	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS ONE, 2015, 10, e0145936.	1.1	15
227	Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget, 2015, 6, 27953-27965.	0.8	14
228	Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?. World Journal of Gastroenterology, 2015, 21, 10336.	1.4	38
229	Postchemoradiotherapy (CRT) pathologic stage classified by American Joint Committee on Cancer (AJCC) staging system to predict prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2015, 33, 158-158.	0.8	0
230	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 566-566.	0.8	0
231	The use of opioids not recommended in guidelines in Taiwan cancer patients.. Journal of Clinical Oncology, 2015, 33, e20721-e20721.	0.8	0
232	Clinical significance of LKB1 protein and gene expression in breast cancer.. Journal of Clinical Oncology, 2015, 33, e11538-e11538.	0.8	0
233	Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.. Journal of Clinical Oncology, 2015, 33, 4074-4074.	0.8	0
234	Primary tumor site as a useful predictor for cetuximab efficacy in KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, e14592-e14592.	0.8	0

#	Article	IF	Citations
235	Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II Î±, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer.. Journal of Clinical Oncology, 2015, 33, 1025-1025.	0.8	0
236	Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations. Anticancer Research, 2015, 35, 4207-14.	0.5	4
237	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. Journal of Hepatocellular Carcinoma, 2014, 1, 85.	1.8	17
238	Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior. Modern Pathology, 2014, 27, 1116-1125.	2.9	19
239	Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence. Seminars in Liver Disease, 2014, 34, 427-434.	1.8	50
240	Distinct Clinicopathological Features and Prognosis of Emerging Young-Female Breast Cancer in an East Asian Country: A Nationwide Cancer Registry-Based Study. Oncologist, 2014, 19, 583-591.	1.9	44
241	Type 2 Diabetes Mellitus Is Associated With Increased Mortality in Chinese Patients Receiving Curative Surgery for Colon Cancer. Oncologist, 2014, 19, 951-958.	1.9	24
242	Reply. Hepatology, 2014, 60, 766-767.	3.6	0
243	Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. International Journal of Cancer, 2014, 135, 492-501.	2.3	19
244	Beware imposters: MAâ€1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large Bâ€cell lymphoma cell lineâ€"A reply: Despite the same 8â€code STR, MAâ€1 and Pfeiffer are cytogenetically diverse. Genes Chromosomes and Cancer, 2014, 53, 211-213.	1.5	3
245	Î²-Catenin<i> (CTNNB1)</i> Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma. Oncology, 2014, 87, 159-166.	0.9	35
246	No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. Breast Cancer Research and Treatment, 2014, 148, 135-142.	1.1	11
247	Potential synergistic antiâ€tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 2021-2031.	1.4	12
248	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology, 2014, 59, 2092-2100.	3.6	235
249	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases. Journal of the Formosan Medical Association, 2014, 113, 577-578.	0.8	4
250	Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin. Molecular Cancer, 2014, 13, 2.	7.9	32
251	Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Supportive Care in Cancer, 2014, 22, 1189-1197.	1.0	13
252	A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 445-451.	1.2	23

#	Article	IF	Citations
253	Sorafenib relieves cellâ€intrinsic and cellâ€extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. International Journal of Cancer, 2014, 134, 319-331.	2.3	102
254	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. Clinical Colorectal Cancer, 2014, 13, 145-155.	1.0	15
255	Preoperative Prognostic Neurologic Index for Glioblastoma Patients Receiving Tumor Resection. Annals of Surgical Oncology, 2014, 21, 3992-3998.	0.7	6
256	Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 661-668.	1.3	57
257	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. Journal of Hepatology, 2014, 60, 313-318.	1.8	47
258	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	0.9	28
259	Abstract 2984: Normalization of tumor vasculature by anti-angiogenesis therapy in metastatic tumor: A clinical study to determine the timing and effect. Cancer Research, 2014, 74, 2984-2984.	0.4	3
260	A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers.. Journal of Clinical Oncology, 2014, 32, 2617-2617.	0.8	6
261	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).. Journal of Clinical Oncology, 2014, 32, TPS4150-TPS4150.	0.8	7
262	A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.. Journal of Clinical Oncology, 2014, 32, TPS4151-TPS4151.	0.8	6
263	A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.. Journal of Clinical Oncology, 2014, 32, TPS4153-TPS4153.	0.8	9
264	OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2014, 32, TPS4155-TPS4155.	0.8	4
265	Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients. PLoS ONE, 2014, 9, e86789.	1.1	18
266	Clinical Activity of Metronomic Chemotherapy in Liver Cancers. , 2014, , 189-202.		0
267	Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).. Journal of Clinical Oncology, 2014, 32, 4100-4100.	0.8	0
268	Risk of second primary malignancies in young patients with colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14533-e14533.	0.8	0
269	RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).. Journal of Clinical Oncology, 2014, 32, TPS4156-TPS4156.	0.8	0
270	Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS2631-TPS2631.	0.8	0

#	Article	IF	Citations
271	The impact of diabetes mellitus on early cervical cancer in Î'sia: A population-based cohort study.. Journal of Clinical Oncology, 2014, 32, e16501-e16501.	0.8	0
272	Association of helicobacter pylori CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma.. Journal of Clinical Oncology, 2014, 32, 8571-8571.	0.8	0
273	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy. Anticancer Research, 2014, 34, 1047-52.	0.5	8
274	Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. Journal of Neuro-Oncology, 2013, 115, 61-70.	1.4	9
275	Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells. Oncology Reports, 2013, 30, 1497-1505.	1.2	17
276	Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab. Annals of Hematology, 2013, 92, 989-992.	0.8	5
277	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (<scp>EPOIHCC</scp>). Liver International, 2013, 33, 327-337.	1.9	70
278	The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast, 2013, 22, 1148-1154.	0.9	3
279	Sorafenib Enhances Radiation-Induced Apoptosis in Hepatocellular Carcinoma by Inhibiting STAT3. International Journal of Radiation Oncology Biology Physics, 2013, 86, 456-462.	0.4	47
280	Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. European Journal of Cancer, 2013, 49, 3486-3496.	1.3	103
281	Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2013, 2, 345-364.	4.2	58
282	Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. Free Radical Biology and Medicine, 2013, 65, 1246-1256.	1.3	54
283	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. Journal of Clinical Oncology, 2013, 31, 3517-3524.	0.8	675
284	Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 2013, 31, 4067-4075.	0.8	678
285	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. Translational Oncology, 2013, 6, 363-369.	1.7	9
286	Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochemical Pharmacology, 2013, 85, 356-366.	2.0	43
287	Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. European Journal of Cancer, 2013, 49, 1458-1466.	1.3	27
288	Sorafenib and its derivative <scp>SC</scp>â€49 sensitize hepatocellular carcinoma cells to <scp>CS</scp>â€1008, a humanized antiâ€TNFRSF10B<scp> (DR</scp>5) antibody. British Journal of Pharmacology, 2013, 168, 658-672.	2.7	19

#	Article	IF	Citations
289	The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme. Oncology, 2013, 84, 326-335.	0.9	10
290	Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?. Liver Cancer, 2013, 2, 93-107.	4.2	35
291	Helicobacter pylori and mucosa-associated lymphoid tissue: what's new. Hematology American Society of Hematology Education Program, 2013, 2013, 109-117.	0.9	48
292	Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. Journal of Clinical Pathology, 2013, 66, 140-145.	1.0	15
293	CYP19Genetic Polymorphism HaplotypeAASAIs Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer. BioMed Research International, 2013, 2013, 1-9.	0.9	10
294	No evidence ofIGH-MALT1-translocation in the Ma-1 cell line-A reply. Genes Chromosomes and Cancer, 2013, 52, 593-594.	1.5	1
295	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed antiâ€angiogenic therapy. Liver International, 2013, 33, 1413-1419.	1.9	15
296	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. Cancer, 2013, 119, 1210-1216.	2.0	13
297	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. Journal of Clinical Oncology, 2013, 31, 1640-1648.	0.8	548
298	Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiation Oncology, 2013, 8, 245.	1.2	26
299	Nuclear Expression of Glioma-Associated Oncogene Homolog 1 and Nuclear Factor-κB Is Associated with a Poor Prognosis of Pancreatic Cancer. Oncology, 2013, 85, 86-94.	0.9	23
300	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. Oncology, 2013, 85, 44-52.	0.9	46
301	The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2013, 85, 312-316.	0.9	6
302	Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway. PLoS ONE, 2013, 8, e66589.	1.1	11
303	Regular statin users and colorectal cancer (CRC) prognosis.. Journal of Clinical Oncology, 2013, 31, 3554-3554.	0.8	1
304	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4099-4099.	0.8	1
305	Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome. PLoS ONE, 2013, 8, e55705.	1.1	37
306	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. PLoS ONE, 2013, 8, e80276.	1.1	23

#	Article	IF	Citations
307	Unique histopathologic features of brain metastases from hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, 169-169.	0.8	0
308	Association of diabetes mellitus with increased mortality in patients receiving curative surgery for colon cancer.. Journal of Clinical Oncology, 2013, 31, 399-399.	0.8	0
309	Prevalence of gene amplifications of SOX-2, c-MET, and FGFR1 in Asian patients with esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, e15127-e15127.	0.8	0
310	Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.. Journal of Clinical Oncology, 2013, 31, TPS4163-TPS4163.	0.8	1
311	Clinicopathologic features and treatment outcome of primary intestinal non-Hodgkin lymphoma: A single center experience.. Journal of Clinical Oncology, 2013, 31, e19523-e19523.	0.8	0
312	Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e15043-e15043.	0.8	0
313	Vascular endothelial growth factor expression in hepatitis C virus (HCV)-related advanced hepatocellular carcinoma (HCC) compared with hepatitis B virus (HBV)-related advanced HCC.. Journal of Clinical Oncology, 2013, 31, 4115-4115.	0.8	8
314	Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF-ÎºB pathway activation through inhibition of BAFF.. Journal of Clinical Oncology, 2013, 31, e13554-e13554.	0.8	0
315	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. Journal of Clinical Oncology, 2013, 31, e14501-e14501.	0.8	0
316	Clinical features of long-term survivors (LTS) of advanced hepatocellular carcinoma undergoing molecular targeted therapy (MTT).. Journal of Clinical Oncology, 2013, 31, e15182-e15182.	0.8	0
317	The Impact of Diabetes Mellitus on Prognosis of Early Breast Cancer in Asia. Oncologist, 2012, 17, 485-491.	1.9	37
318	Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy. Clinical Cancer Research, 2012, 18, 3992-3997.	3.2	41
319	Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1â€"Mediated Inhibition of STAT3. Molecular Cancer Therapeutics, 2012, 11, 452-463.	1.9	119
320	Primary Squamous Cell Carcinoma of the Thyroid With Cardiac Metastases and Right Ventricle Outflow Tract Obstruction. Journal of Clinical Oncology, 2012, 30, e260-e263.	0.8	16
321	Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. Oncologist, 2012, 17, 856-862.	1.9	32
322	Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. Oncologist, 2012, 17, 970-977.	1.9	9
323	Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. Journal of Human Genetics, 2012, 57, 130-138.	1.1	21
324	Perspectives on The Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy. Liver Cancer, 2012, 1, 168-176.	4.2	19

#	Article	IF	Citations
325	Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pyloriâ€"positive gastric diffuse large B-cell lymphomas. Blood, 2012, 119, 4838-4844.	0.6	123
326	Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. Leukemia and Lymphoma, 2012, 53, 1515-1524.	0.6	32
327	Radiosensitizing Effect of a Phenylbutyrate-Derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, e181-e189.	0.4	22
328	Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Journal of Hepatology, 2012, 56, 1097-1103.	1.8	91
329	Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Letters, 2012, 317, 9-15.	3.2	29
330	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asiaâ€"Pacific trial. European Journal of Cancer, 2012, 48, 1452-1465.	1.3	240
331	BCL10GFP fusion protein as a substrate for analysis of determinants required for Mucosa-Associated Lymphoid Tissue 1 (MALT1)-mediated cleavage. Journal of Biomedical Science, 2012, 19, 85.	2.6	2
332	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e470-e481.	5.1	70
333	Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells. Neoplasia, 2012, 14, 463-IN3.	2.3	36
334	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. Oncology, 2012, 82, 59-66.	0.9	29
335	A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression. Oncology, 2012, 82, 275-289.	0.9	35
336	Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer, 2012, 12, 620.	1.1	16
337	KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells. PLoS ONE, 2012, 7, e50701.	1.1	44
338	Functional Characterization of Glycine N-Methyltransferase and Its Interactive Protein DEPDC6/DEPTOR in Hepatocellular Carcinoma. Molecular Medicine, 2012, 18, 286-296.	1.9	54
339	The emerging epidemic of estrogenâ€related cancers in young women in a developing Asian country. International Journal of Cancer, 2012, 130, 2629-2637.	2.3	47
340	Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression. Gastric Cancer, 2012, 15, 265-280.	2.7	17
341	Authorâ€™s reply: Vitamin A and gastric cancer risk. Gastric Cancer, 2012, 15, 344-344.	2.7	16
342	Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Biochemical Pharmacology, 2012, 83, 769-777.	2.0	39

#	Article	IF	Citations
343	Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochemical Pharmacology, 2012, 84, 268-277.	2.0	52
344	CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncology, 2012, 48, 585-593.	0.8	54
345	Expression of BCL10 in cervical cancer has a role in the regulation of cell growth through the activation of NF-ÎºBâ€dependent cyclin D1 signaling. Gynecologic Oncology, 2012, 126, 245-251.	0.6	18
346	Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. Annals of Hematology, 2012, 91, 291-294.	0.8	10
347	Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study.. Journal of Clinical Oncology, 2012, 30, 1079-1079.	0.8	19
348	Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 311-311.	0.8	1
349	An open-label, randomized phase II study comparing first-line treatment with dovitinib (TKI258) versus sorafenib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2012, 30, TPS4147-TPS4147.	0.8	0
350	The first two lines of chemotherapy for anthracycline-naÃ¯ve metastatic breast cancer: A comparative study of efficacy between anthracyclines and nonanthracyclines.. Journal of Clinical Oncology, 2012, 30, 1061-1061.	0.8	0
351	Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan.. Journal of Clinical Oncology, 2012, 30, 4035-4035.	0.8	2
352	Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e14576-e14576.	0.8	0
353	Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, e14617-e14617.	0.8	0
354	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. Anticancer Research, 2012, 32, 4865-70.	0.5	11
355	Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. Oncology, 2011, 81, 158-164.	0.9	104
356	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. European Journal of Cancer, 2011, 47, 1244-1257.	1.3	17
357	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Journal of Hepatology, 2011, 55, 858-865.	1.8	114
358	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. Journal of Hepatology, 2011, 55, 1041-1048.	1.8	149
359	Recent Advances in the Treatment of Metastatic Colorectal Cancer in Taiwan. Journal of the Formosan Medical Association, 2011, 110, 1-3.	0.8	1
360	Induction Chemotherapy With Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, e749-e757.	0.4	20

#	Article	IF	Citations
361	Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Anti-Cancer Drugs, 2011, 22, 290-298.	0.7	4
362	Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Research and Treatment, 2011, 130, 345-351.	1.1	98
363	A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Cancer Chemotherapy and Pharmacology, 2011, 67, 1281-1289.	1.1	5
364	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. Cancer Chemotherapy and Pharmacology, 2011, 68, 1387-1395.	1.1	14
365	Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. European Journal of Medicinal Chemistry, 2011, 46, 2845-2851.	2.6	29
366	IÎºB kinases increase Myc protein stability and enhance progression of breast cancer cells. Molecular Cancer, 2011, 10, 53.	7.9	25
367	Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. Journal of Translational Medicine, 2011, 9, 120.	1.8	22
368	Establishment of a novel MALT lymphoma cell line, maâ€1, from a patient with t(14;18)(q32;q21)â€positive Helicobacter Pyloriâ€Independent Gastric MALT Lymphoma. Genes Chromosomes and Cancer, 2011, 50, 908-921.	1.5	9
369	Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy. Oncologist, 2011, 16, 82-86.	1.9	34
370	Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?. Journal of Clinical Pathology, 2011, 64, 781-787.	1.0	10
371	Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib. Clinical Cancer Research, 2011, 17, 4504-4512.	3.2	83
372	Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A. Molecular Cancer Therapeutics, 2011, 10, 892-901.	1.9	37
373	Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 155-161.	1.3	270
374	Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma. Oncology, 2011, 81, 372-380.	0.9	46
375	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. Oncology, 2011, 81, 143-150.	0.9	15
376	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. Oncology, 2011, 81, 98-103.	0.9	19
377	Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis, 2011, 32, 812-821.	1.3	43
378	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. Anticancer Research, 2011, 31, 4007-11.	0.5	11

#	Article	IF	Citations
379	Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. Journal of Zhejiang University: Science B, 2010, 11, 1-9.	1.3	12
380	Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma. Annals of Hematology, 2010, 89, 431-436.	0.8	1
381	Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. Journal of Gastroenterology, 2010, 45, 794-807.	2.3	61
382	Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicology and Applied Pharmacology, 2010, 248, 111-121.	1.3	109
383	Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer, 2010, 10, 461.	1.1	104
384	Early alphaâ€fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer, 2010, 116, 4590-4596.	2.0	154
385	The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Molecular Carcinogenesis, 2010, 49, 235-246.	1.3	38
386	Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. Japanese Journal of Clinical Oncology, 2010, 40, 286-293.	0.6	27
387	Induction of DNA Damage-Inducible Gene GADD45Î² Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2010, 70, 9309-9318.	0.4	76
388	E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Modern Pathology, 2010, 23, 1507-1517.	2.9	48
389	Liver Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i19-i27.	0.6	65
390	Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. Clinical Cancer Research, 2010, 16, 5189-5199.	3.2	155
391	Translocation of Helicobacter pylori CagA into Human B Lymphocytes, the Origin of Mucosa-Associated Lymphoid Tissue Lymphoma. Cancer Research, 2010, 70, 5740-5748.	0.4	79
392	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer, 2010, 68, 484-490.	0.9	29
393	Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma. Journal of Experimental and Clinical Medicine, 2010, 2, 93-103.	0.2	21
394	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. Journal of Hepatology, 2010, 52, 88-95.	1.8	64
395	Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology, 2010, 52, 889-894.	1.8	125
396	Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Letters, 2010, 298, 195-203.	3.2	20

#	Article	IF	Citations
397	Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials, 2010, 31, 55-61.	0.8	46
398	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. Journal of Hepatology, 2010, 53, 126-131.	1.8	124
399	Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions. Journal of the Formosan Medical Association, 2010, 109, 362-368.	0.8	28
400	Abstract 3759: Discordance of the immunohistochemical expression of phospho-Akt and phosphor-ERK between paired biopsy and hepatectomy specimens of hepatocellular carcinoma. , 2010, , .		1
401	Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1807-1814.	1.1	103
402	Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 417-423.	1.1	24
403	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. Clinical Cancer Research, 2009, 15, 5820-5828.	3.2	35
404	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. Journal of Biological Chemistry, 2009, 284, 11121-11133.	1.6	79
405	National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital. Drug Information Journal, 2009, 43, 361-363.	0.5	3
406	Gemcitabineâ€based combination chemotherapy as salvage treatment for refractory or relapsing aggressive nonâ€Hodgkin's lymphoma. American Journal of Hematology, 2009, 84, 457-459.	2.0	1
407	Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy. Hepatology, 2009, 50, 654-655.	3.6	3
408	Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 1173-1179.	1.1	20
409	Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 442-448.	0.4	27
410	Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling Pathway. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1545-1552.	0.4	25
411	Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method â€“ Analysis of 2010 Taiwanese patients. European Journal of Cancer, 2009, 45, 1630-1639.	1.3	72
412	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 518-527.	1.8	42
413	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer, 2009, 64, 346-351.	0.9	43
414	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. Expert Review of Clinical Pharmacology, 2009, 2, 129-136.	1.3	11

#	Article	IF	Citations
415	Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast â€“ a review of 42 primary and secondary cases in Taiwanese patients. Leukemia and Lymphoma, 2009, 50, 918-924.	0.6	29
416	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2009, 10, 25-34.	5.1	5,104
417	Treatment of Hepatocellular Carcinoma with Thalidomide: Assessment with Power Doppler Ultrasound. , 2009, , 277-286.		0
418	Lamivudine and Hepatitis B Reactivation. Annals of Internal Medicine, 2009, 151, 141.	2.0	0
419	Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway. Molecular Carcinogenesis, 2008, 47, 956-963.	1.3	40
420	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology, 2008, 47, 844-853.	3.6	277
421	Comprehensive Locoregional Treatment and Systemic Therapy for Postmastectomy Isolated Locoregional Recurrence. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1456-1464.	0.4	38
422	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. Lung Cancer, 2008, 60, 215-221.	0.9	2
423	Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinomaâ€"A randomized phase II trial. Lung Cancer, 2008, 62, 334-343.	0.9	14
424	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. Cancer Research, 2008, 68, 6698-6707.	0.4	109
425	Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 659-661.	0.8	8
426	Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Letters, 2008, 268, 314-324.	3.2	187
427	NF-ÎºB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochemical and Biophysical Research Communications, 2008, 376, 283-287.	1.0	23
428	SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Nonâ€"Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology, 2008, 26, 2745-2753.	0.8	249
429	OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Speciesâ€"Related Autophagy in Hepatocellular Carcinoma. Cancer Research, 2008, 68, 9348-9357.	0.4	131
430	Breast Cancerâ€"Associated Fibroblasts Confer AKT1-Mediated Epigenetic Silencing of Cystatin M in Epithelial Cells. Cancer Research, 2008, 68, 10257-10266.	0.4	65
431	FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C Î´ Signaling. Cancer Research, 2008, 68, 1204-1212.	0.4	99
432	Overexpression of B cellâ€"activating factor of TNF family (BAFF) is associated with Helicobacter pyloriâ€"independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood, 2008, 112, 2927-2934.	0.6	52

#	Article	IF	Citations
433	Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma. Annals of Surgery, 2008, 247, 265-269.	2.1	17
434	Histone Deacetylase Inhibitors in Cancer Therapy. , 2008, , 381-398.		0
435	Prognostic Factors in Extrapulmonary Small Cell Carcinomas. Oncology, 2007, 72, 181-187.	0.9	20
436	Sulfasalazine Suppresses Drug Resistance and Invasiveness of Lung Adenocarcinoma Cells Expressing AXL. Cancer Research, 2007, 67, 3878-3887.	0.4	97
437	Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells. Clinical Cancer Research, 2007, 13, 851-857.	3.2	94
438	Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anti-Cancer Drugs, 2007, 18, 487-491.	0.7	37
439	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anti-Cancer Drugs, 2007, 18, 703-708.	0.7	8
440	Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens. Urology, 2007, 69, 479-484.	0.5	24
441	Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 207-213.	0.8	4
442	Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma. Journal of Urology, 2007, 177, 84-89.	0.2	24
443	A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer, 2007, 56, 89-95.	0.9	11
444	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology, 2007, 46, 1119-1130.	3.6	84
445	Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology, 2007, 2, 199-210.	1.7	6
446	Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer, 2006, 53, 303-310.	0.9	38
447	Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 531-536.	1.4	7
448	Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 874-879.	1.4	9
449	Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Investigational New Drugs, 2006, 25, 77-84.	1.2	107
450	Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma. Cancer, 2006, 106, 1269-1275.	2.0	23

#	Article	IF	Citations
451	Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. International Journal of Cancer, 2006, 118, 773-779.	2.3	63
452	Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.. Clinical Cancer Research, 2006, 12, 1152-1156.	3.2	118
453	Difference in the Incidence Trend of Nasopharyngeal and Oropharyngeal Carcinomas in Taiwan: Implication from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 856-861.	1.1	65
454	Association of T-Cell Regulatory Gene Polymorphisms With Susceptibility to Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Journal of Clinical Oncology, 2006, 24, 3483-3489.	0.8	80
455	Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-Î°B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. Journal of Endocrinology, 2006, 188, 311-319.	1.2	19
456	A Pathway for Tumor Necrosis Factor-Î±-induced Bcl10 Nuclear Translocation. Journal of Biological Chemistry, 2006, 281, 167-175.	1.6	39
457	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anti-Cancer Drugs, 2005, 16, 739-742.	0.7	2
458	Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood, 2005, 106, 1037-1041.	0.6	74
459	Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective. Cancer Chemotherapy and Pharmacology, 2005, 55, 170-178.	1.1	23
460	Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein. Cancer Research, 2005, 65, 6943-6949.	0.4	93
461	Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1986-1990.	1.1	130
462	Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors. Radiology, 2005, 235, 509-516.	3.6	26
463	Long-Term Results of Antiâ€“ Helicobacter pylori Therapy in Early-Stage Gastric High-Grade Transformed MALT Lymphoma. Journal of the National Cancer Institute, 2005, 97, 1345-1353.	3.0	179
464	Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment. Oncology, 2005, 68, 350-355.	0.9	5
465	Inhibitors of Epidermoid Growth Factor Receptor Suppress Cell Growth and Enhance Chemosensitivity of Nasopharyngeal Cancer Cells in vitro. Oncology, 2005, 68, 538-547.	0.9	38
466	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. Oncology, 2005, 69, 88-95.	0.9	19
467	Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Human Molecular Genetics, 2005, 14, 1465-1474.	1.4	91
468	Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials. Lung Cancer, 2005, 48, 275-280.	0.9	8

#	Article	IF	Citations
469	Expression of CD86 and increased infiltration of NK cells are associated withHelicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma. World Journal of Gastroenterology, 2005, 11, 4357.	1.4	17
470	Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World Journal of Gastroenterology, 2005, 11, 5283.	1.4	18
471	Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World Journal of Gastroenterology, 2005, 11, 6373.	1.4	25
472	Nuclear Expression of BCL10 or Nuclear Factor Kappa B Predicts Helicobacter pyloriâ€"Independent Status of Early-Stage, High-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphomas. Journal of Clinical Oncology, 2004, 22, 3491-3497.	0.8	59
473	Suppression of MEK/ERK Signaling Pathway Enhances Cisplatin-induced NF-ÎºB Activation by Protein Phosphatase 4-mediated NF-ÎºB p65 Thr Dephosphorylation. Journal of Biological Chemistry, 2004, 279, 26143-26148.	1.6	97
474	Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides. Clinical Cancer Research, 2004, 10, 2645-2651.	3.2	77
475	Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene, 2004, 23, 3580-3588.	2.6	83
476	Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate, 2004, 60, 120-129.	1.2	76
477	Promoter polymorphisms of tumor necrosis factor-? are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma. International Journal of Cancer, 2004, 110, 695-700.	2.3	56
478	Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells. Anti-Cancer Drugs, 2004, 15, 371-376.	0.7	31
479	Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepato-Gastroenterology, 2004, 51, 815-9.	0.5	6
480	Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2004, 103, 483-95.	0.8	19
481	Effect of interleukin-1beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica, 2004, 89, 1015-7.	1.7	13
482	Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Research, 2004, 24, 3035-40.	0.5	43
483	Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. Quality of Life Research, 2003, 12, 503-517.	1.5	29
484	Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology, 2003, 37, 1320-1328.	3.6	256
485	Involvement of nuclear transcription factor-ÎºB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochemical Pharmacology, 2003, 66, 25-33.	2.0	38
486	Direct cardiac effects of As2O3 in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration. Toxicology and Applied Pharmacology, 2003, 189, 214-220.	1.3	28

#	Article	IF	Citations
487	Hepatitis B Virus X Protein Activates a Survival Signaling by Linking Src to Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry, 2003, 278, 31807-31813.	1.6	53
488	Low-Dose Thalidomide Treatment for Advanced Hepatocellular Carcinoma. Oncology, 2003, 65, 242-249.	0.9	85
489	Increased Risk of Parvovirus B19 Infection in Young Adult Cancer Patients Receiving Multiple Courses of Chemotherapy. Journal of Clinical Microbiology, 2002, 40, 3909-3912.	1.8	34
490	Prognostic Value of Multidrug Resistance 1, Glutathione-S-Transferase-Ï€ and p53 in Advanced Nasopharyngeal Carcinoma Treated with Systemic Chemotherapy. Oncology, 2002, 62, 305-312.	0.9	29
491	Combination of 13-cis Retinoic Acid and Interferon-Î± in the Treatment of Recurrent or Refractory Peripheral T-cell Lymphoma. Leukemia and Lymphoma, 2002, 43, 1415-1420.	0.6	8
492	Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFÎºB activation. Biochemical Pharmacology, 2002, 63, 1423-1430.	2.0	126
493	Basal levels and patterns of anticancer drug-induced activation of nuclear factor-ÎºB (NF-ÎºB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochemical Pharmacology, 2002, 63, 1709-1716.	2.0	159
494	The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells*. Molecular Carcinogenesis, 2002, 33, 137-145.	1.3	67
495	High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. International Journal of Cancer, 2002, 101, 519-525.	2.3	109
496	P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. International Journal of Cancer, 2002, 97, 451-457.	2.3	65
497	HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer, 2002, 94, 415-420.	2.0	42
498	Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naÃ¯ve patients with locally advanced or metastatic breast carcinoma. Cancer, 2002, 95, 2044-2050.	2.0	10
499	A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Research, 2002, 22, 3621-7.	0.5	7
500	Nuclear Extracellular Signal-Regulated Kinase 2 Phosphorylates p53 at Thr55 in Response to Doxorubicin. Biochemical and Biophysical Research Communications, 2001, 284, 880-886.	1.0	34
501	Prospective Study of Helicobacter pylori Eradication Therapy in Stage I_E High-Grade Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach. Journal of Clinical Oncology, 2001, 19, 4245-4251.	0.8	100
502	Comparison of MALT and non-MALT primary large cell lymphoma of the stomach. Cancer, 2001, 91, 49-56.	2.0	11
503	Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. American Journal of Hematology, 2000, 64, 175-179.	2.0	35
504	Hepatitis B Virus X Protein Inhibits Transforming Growth Factor-Î²-induced Apoptosis through the Activation of Phosphatidylinositol 3-Kinase Pathway. Journal of Biological Chemistry, 2000, 275, 25858-25864.	1.6	176

#	Article	IF	Citations
505	Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food and Chemical Toxicology, 2000, 38, 991-995.	1.8	168
506	Retinoic acidâ€"induced apoptotic pathway in T-cell lymphoma. Experimental Hematology, 2000, 28, 1441-1450.	0.2	23
507	Minimal Toxicity to Myeloid Progenitor Cells of Weekly24â€Hr Infusion of Highâ€Dose 5â€Fluorouracil: Direct Evidence from Colony Forming Unitâ€Granulocyte andMonocyte (CFUâ€GM) Clonogenic Assay. Basic and Clinical Pharmacology and Toxicology, 2000, 86, 122-124.	0.0	1
508	Hypermethylation of the p16 Gene in Sporadic T3N0M0 Stage Colorectal Cancers: Association with DNA Replication Error and Shorter Survival. Oncology, 1999, 57, 149-156.	0.9	70
509	High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. , 1999, 86, 415-420.		14
510	Quiescent nasal T/NK cell lymphoma manifested as primary central nervous system lymphoma. , 1999, 60, 161-163.		32
511	High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers. Breast Cancer Research and Treatment, 1998, 49, 237-244.	1.1	2
512	Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. Oncogene, 1998, 17, 2225-2234.	2.6	35
513	5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply. British Journal of Cancer, 1998, 77, 1711-1712.	2.9	3
514	High expression of thymidylate synthase is Associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. , 1998, 82, 1626-1631.		93
515	Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma. , 1998, 82, 1946-1951.		53
516	Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. British Journal of Haematology, 1998, 100, 769-772.	1.2	29
517	Transactivation of the human MDR1 gene by hepatitis B virus X gene product. Journal of Hepatology, 1998, 29, 872-878.	1.8	12
518	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochemical Pharmacology, 1998, 55, 523-531.	2.0	54
519	Megestrol acetate antagonizes cisplatin cytotoxicity. Anti-Cancer Drugs, 1998, 9, 733-738.	0.7	3
520	Relatively Low Expression of Multidrug Resistance-1 (MDR-1) and Its Possible Clinical Implication in Gastric Cancers. Journal of Clinical Gastroenterology, 1998, 26, 274-278.	1.1	10
521	Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Advanced Gastric Cancers. Oncology, 1997, 54, 275-280.	0.9	56
522	Transforming growth factor Î²1 attenuates ceramide-induced CPP32/Yama activation and apoptosis in human leukaemic HL-60 cells. Biochemical Journal, 1997, 327, 663-667.	1.7	21

#	Article	IF	Citations
523	Tax of the Human T-Lymphotropic Virus Type I Transactivates Promoter of theMDR-1Gene. Biochemical and Biophysical Research Communications, 1997, 238, 482-486.	1.0	7
524	Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instability. Cancer Letters, 1997, 112, 161-166.	3.2	25
525	Early Gastric Cancer as a Possible Cause of Cauda Equina Syndrome and Disseminated Intravascular Coagulation. Digestive Endoscopy, 1997, 9, 51-55.	1.3	0
526	Expression of Pâ€glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 569-575.	1.4	36
527	Stability of curcumin in buffer solutions and characterization of its degradation products. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 1867-1876.	1.4	1,401
528	Expression of MDR-1 Gene in Transitional Cell Carcinoma and its Correlation with Chemotherapy Response. Journal of Urology, 1996, 156, 271-275.	0.2	28
529	Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. , 1996, 77, 872-877.		30
530	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-Cis retinoic acid. , 1996, 78, 1805-1812.		35
531	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13-Cis retinoic acid. , 1996, 78, 1805.		3
532	Primary T Cell Leptomeningeal Lymphoma â€“ Successful Treatment with Systemic Chemotherapy. Oncology, 1995, 52, 501-504.	0.9	11
533	Clinicopathologic Characteristics of Helicobacter Pyloric Seropositive Gastric Adenocarcinomas. Journal of Clinical Gastroenterology, 1995, 21, 203-207.	1.1	12
534	Hemophagocytic Syndrome in Epstein-Barr Virus-Associated T-Lymphoproliferative Disorders: Disease Spectrum, Pathogenesis, and Management. Leukemia and Lymphoma, 1995, 19, 401-406.	0.6	123
535	Tamoxifen Enhances the Chemosensitivity of Bladder Carcinoma Cells. Journal of Urology, 1995, 154, 601-605.	0.2	30
536	Characteristic clinicopathologic features of adult B-cell lymphoblastic lymphoma with special emphasis on differential diagnosis with an atypical form probably of blastic lymphocytic lymphoma of intermediate differentiation origin. Cancer, 1994, 73, 706-710.	2.0	18
537	Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. British Journal of Haematology, 1994, 87, 535-543.	1.2	68
538	Characteristic clinicopathologic features of epstein-barr virusâ€”associated peripheral T-cell lymphoma. Cancer, 1993, 72, 909-916.	2.0	84
539	Epsteinâ€”barr virus-containing t-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis. Cancer, 1993, 72, 2019-2027.	2.0	88
540	Retinoic acid-induced apoptosis and regression of a refractory Epstein-Barr virus-containing T cell lymphoma expressing multidrug-resistance phenotypes. British Journal of Haematology, 1993, 85, 826-828.	1.2	20

#	Article	IF	Citations
541	Menadione-induced DNA damage in a human tumor cell line. Biochemical Pharmacology, 1991, 42, 1961-1968.	2.0	66
542	13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki-1 lymphoma. Cancer, 1991, 67, 2490-2494.	2.0	23
543	Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies. Annals of Oncology, 1991, 2, 151-155.	0.6	22
544	Revisiting the Full Spectrum of Helicobacter pylori-Related Gastric Lymphoma. , 0, , .		0
545	Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma. Esophagus, 0, , .	1.0	0